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In December 2019, the World Health Organization (WHO) was 
informed of an increasing number of pneumonia cases observed in 
Wuhan City, China.[1] The disease is caused by the pathogen severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2),[2] and has 
since been termed coronavirus disease 2019 (COVID-19).[1] COVID-
19 was declared a global pandemic,[1] with ~64 million cases and 
more than 1.4 million deaths reported to date.[3] 
There is currently no vaccine or cure for COVID-19. Current 
recommendations aim to limit viral spread by using non-
pharmacological interventions such as maintaining social distancing, 
wearing protective face masks, hand washing, sanitisation and 
where necessary, self-isolation following a positive diagnosis or 
exposure to a SARS-CoV-2-infected person. Symptomatic patients 
and those presenting with acute respiratory infections may require 
supplemental oxygen, corticosteroids (dexamethasone and others) 
and systemic anticoagulation. Attempts have been made to reduce 
viral load using oseltamivir, normally used to treat influenza type 
A and B, and remdesivir, a repurposed drug developed for Ebola. 
Treatments aimed at reducing the impact of the cytokine release 
syndrome (CRS) or cytokine storm include tocilizumab, an anti-IL-6 
receptor monoclonal antibody.[4,5] Clinical trials are underway to 
determine the effects of convalescent plasma from patients with high 
titres of SARS-CoV-2, administered within 72 hours of diagnosis,[4] 
and the data to date are equivocal. 
Disease severity is greater in some patients than in others. Most 
COVID-19 patients are asymptomatic or exhibit mild to moderate 
disease. A minority exhibit severe complications including acute 
respiratory distress syndrome and multiple organ failure, requiring 
hospitalisation with supplemental oxygen and assisted ventilation.[6-8] 
Older people, men and those with underlying conditions are at 
higher risk of severe illness. Risk factors for severe illness and 
death include hypertension, cardiovascular disease, diabetes, chronic 
kidney disease, chronic obstructive pulmonary disease (COPD), 
cancer and obesity.[9-12]
Selection criteria
Relevant literature was retrieved from PubMed and Google Scholar 
using the key words ‘COVID-19 and comorbidities’, ‘obesity and 
COVID-19’, ‘obesity and ACE2’, ‘obesity and immune response’ and 
‘obesity and cellular and molecular mechanisms’. From these sources, 
we evaluated and selected articles on the epidemiology, and cellular 
and molecular mechanisms of COVID-19 in the context of obesity. 
This is not an exhaustive systematic review or a meta-analysis but 
rather a descriptive review in an ever-changing field of some of the 
key pathogenetic mechanisms to have emerged in a disease whose 
existence we have known about for less than a year.
Obesity and COVID-19
Obesity is a global pandemic and has almost tripled in prevalence 
since the 1970s. The WHO defines obesity as the accumulation of fat, 
which can negatively affect health. Overweight people have a body 
mass index (BMI) >25 and a BMI ≥30 is defined as obesity. Obesity 
affected more than 650 million people globally in 2016 and is a risk 
factor for cardiovascular disease, type 2 diabetes mellitus, kidney 
disease and cancer. An increase in BMI and adiposity also increases 
the risk of contracting infections.[14] Developed countries have a 
higher prevalence of obesity, but urbanisation and globalisation have 
led to a surge of obesity in developing countries.[15]
COVID-19 patients with obesity, and mostly males, present with 
severe disease. They often require hospitalisation and mechanical 
ventilation, are admitted to the intensive care unit (ICU) and have 
a higher probability of mortality.[9,16-21] Data from Africa are lacking, 
but global trends suggest that obesity is also a risk factor for more 
severe COVID-19 disease in African populations. 
The strong association between COVID-19 and obesity is not 
well understood. In this article, we review the potential cellular and 
molecular mechanisms contributing to severe COVID-19 in obese 
patients. 
The pathophysiology of obesity and 
COVID-19
Immunopathogenesis
Obesity in the general population is associated with a depressed 
immune system and chronic low-grade inflammation characterised 
by an increase in adipokines and pro-inflammatory cytokines. [22] 
When obese patients are infected with COVID-19, the two 
pathologies appear to act in concert to further impair immune 
function and elicit a more severe inflammatory response, resulting 
in more severe COVID-19 disease.[21,23,24] The CRS, an uncontrolled 
and excessive production of pro-inflammatory cytokines has been 
observed in critically ill COVID-19 patients.[25-27] Various cytokines 
are released, including interleukin-1 (IL-1), IL-6 and IL-10, as well as 
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growth factors, colony-stimulating factors, interferons, macrophage 
inflammatory proteins and tumour necrosis factor alpha (TNFα). 
Most studies have found significantly increased levels of IL-6 and 
TNFα in COVID-19 patients.[25,26] These pro-inflammatory cytokines 
increase vascular permeability, which causes blood cells and fluid to 
enter alveoli, producing symptoms such as dyspnoea.[28] The CRS is 
believed to be responsible for the presentation of acute respiratory 
distress syndrome (ARDS) and multi-organ failure in some COVID-
19 patients.[25,26] 
To respond effectively against viral infections, our immune systems 
rely on optimally functioning T cells. Low T cell counts are a known 
risk factor and predictor of poor prognosis and mortality in COVID-
19 patients.[29,30] In Wuhan, China, patients with severe COVID-19 
had significantly fewer cytotoxic and helper T cells.[30] Defective T 
cell-mediated immune responses have also been observed in obese 
patients, who are more likely to be hospitalised if they acquire 
respiratory infections.[31] 
Immune dysregulation in obese people may also include reduced 
antiviral cytokines, diminished natural killer cell activity and 
dysfunctional macrophages.[32-34] Impaired activation and functioning 
of CD4+ and CD8+ T cells have been observed in overweight and obese 
individuals who were infected with the H1N1 virus, which may have 
contributed to disease severity and mortality.[35] When infected with 
influenza A/Puerto Rico/8/34 (A/PR8), obese mice showed reduced 
expression of interferon alpha (INFα) and INFβ in the early stages of 
infection and this remained low throughout the infection.[32] These 
mice had diminished natural killer cell proliferation and activity 
in the lungs.[32] Other forms of immune dysregulation observed in 
obese mice infected with influenza included reduced expression 
of monocyte chemoattractant protein 1 (MCP-1), regulated upon 
activation normal T cell expressed and secreted (RANTES) and 
a delayed expression of the essential cytokines, TNFα and IL6.[32] 
Obese people who had severe H1N1 disease had reduced macrophage 
activation and cytotoxic activity.[33] It is possible that the dysfunction 
in the innate immune system of obese patients may also contribute to 
the severity of COVID-19 symptoms.
Another link between the severity of COVID-19 disease and obesity 
may be the chronic production of leptin due to an increased number 
of adipocytes.[36,37] The immune response becomes dysregulated when 
T cells and natural killer cells become resistant to leptin.[38] High levels 
of leptin were associated with disease severity and mortality in obese 
mice infected with H1N1.[39] Leptin also increases the production 
of leukotrienes by alveolar macrophages and may ultimately cause 
pulmonary inflammation.[40] 
Adipose tissue, obesity and receptors for SARS-CoV-2
Adipose tissue expresses receptors such as angiotensin-converting 
enzyme-2 (ACE2) and dipeptidyl peptidase 4 (DPP4), which 
facilitate the entry of SARS-CoV-2 into human cells and increase 
viral load.[41] 
In the lungs, SARS-CoV-2 binds to the ACE2 receptor, upregulating 
the expression of ACE2 and damaging alveolar cells.[42] The ACE2 
receptor is overexpressed in the adipose tissue of COVID-19 
patients.[43,44] Since obese people have more adipose tissue, they are 
expected to have more ACE2 receptors. ACE2 receptors are expressed 
in monocytes and macrophages,[45] which are also more prevalent 
in the adipose tissue of obese people.[46,47] It is therefore likely 
that adipose tissue acts as a viral reservoir and possibly allows for 
inter-organ transmission.[43,44] When cells bearing ACE2 receptors are 
infected, their immunomodulatory activity is impaired and they produce 
proinflammatory factors which contribute to inflammation.[48] Monocytes 
expressing ACE2 are involved in regulating blood vessel homeostasis 
through the renin-angiotensin-aldosterone system (RAAS). When 
SARS-CoV-2 activates ACE2 on monocytes, this disturbs the RAAS, 
resulting in acute coronary syndrome.[49] 
SARS-CoV-2 may also enter cells of the respiratory tract via DPP4, 
a receptor used by the middle east respiratory syndrome coronavirus 
(MERS-CoV)[50] and also known as cluster of differentiation 26 
(CD26).[51,52] DPP4 is a membrane-bound glycoprotein with multiple 
functions including glucose and insulin metabolism and immune 
regulation.[53] DPP4 was identified as a potential SARS-CoV-2 
receptor using bioinformatic and protein-docking prediction tools.[50] 
In obese people, DPP4 is overexpressed in visceral adipose tissue and 
the liver.[54,55] DPP4 has immunomodulatory activity, activating and 
causing the proliferation of T cells and production of cytokines, and 
potentially contributing to and exacerbating hyperinflammation.[54-56] 
Obesity-associated comorbidities and SARS-CoV-2
Obesity is associated with various comorbidities that may contribute 
to the severity of COVID-19. Obese people are disproportionately 
affected by hypertension, type 2 diabetes, pulmonary diseases and 
cancer,[57,58] which have also been identified as risk factors for severe 
COVID-19.[59] 
Obesity affects the functioning of the respiratory system and 
is associated with several respiratory conditions including sleep 
apnoea, asthma, obesity hypoventilation syndrome, COPD, 
pulmonary hypertension, aspiration pneumonia, pulmonary 
embolism (PE),[14,60,61] and respiratory infection.[31] Obese people 
are more likely to accumulate adipose tissue around the upper 
airways, chest wall and abdomen, impairing the mechanics of the 
lungs.[62] Obesity is also a risk factor for venous thromboembolic 
diseases, which include deep vein thrombosis and PE. Recent 
comparisons suggest that overweight or obese COVID-19 patients 
are more prone to developing PE, possibly due to the presence 
of excess adipose tissue.[63,64] The risk of thrombosis increases 
with increasing BMI and waist circumference. Thromboembolic 
disease is caused by chronic inflammation, adipokines, an increase 
in coagulation activity, a decrease in fibrinolytic activity and 
procoagulant microparticles.[65] 
Obesity is also associated with the development and progression 
of chronic kidney disease and end-stage renal disease.[66] Pre-
existing or underlying kidney disease were identified as risk factors 
for severe COVID-19 (83.93%) and related mortality (53.33%) in a 
recent meta-analysis.[67] 
Obesity and COVID-19 in South Africa
The prevalence of obesity in South Africa (SA) is increasing rapidly, 
with at least 68% of women and 31% of men reported as being either 
overweight or obese in 2016.[68] In addition, 13.5% of school-going 
children between the ages of 6 and 14 years were reported to be 
overweight or obese, which is above the 10% global prevalence.[69] In 
a country with high rates of unemployment, poverty and infectious 
diseases such as HIV and tuberculosis, obesity and its associated 
comorbidities have a negative impact on the livelihoods of many 
people. The disease burden leads to an increase in healthcare costs at 
both the individual level and that of the healthcare system.[70] 
Obesity in SA is driven by high levels of poverty, unemployment 
and low income.[71] In the first quarter of 2020, Statistics South Africa 
(Stats SA) reported that the unemployment rate was 30.1% and 
~40 000 jobs had been shed across various sectors.[72] In addition to 
this, 35.1 million SA adults live below the upper-bound poverty line 
of ZAR1 227 per month.[73, 74] People from low-income households 
tend to buy less expensive foods which are gastronomically filling and 
energy-dense, but rich in starch, fat and sugar.[71] The surge in obesity 
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in developing countries such as SA is associated with urbanisation 
and globalisation,[15] and the increased intake of high-calorie fast 
foods and the consumption of sugar-sweetened beverages.[15,71] 
Insufficient physical activity and a sedentary lifestyle are also 
complicit in weight gain and obesity.[71] 
Many countries have implemented strategies that limit physical 
activity to curb the spread of COVID-19, which may have increased 
the prevalence of obesity. On the 26 March 2020, SA went into an 
official lockdown due to the COVID-19 pandemic. Restrictions 
included staying indoors, working remotely, closing of gyms and 
limited outdoor exercise.[75] In response, many people changed 
their eating patterns and switched to a more sedentary lifestyle, 
which created an obesogenic environment. Recently the lockdown 
restrictions were eased to stimulate economic activity[75] and places 
selling fast-food were first to open, with fatty and processed foods 
becoming easily available to the public. Due to a fear of contracting 
COVID-19, many SA citizens abandoned or froze their gym 
memberships and have reduced their levels of physical activity. 
This could exacerbate the rising prevalence of obesity in SA, further 
increasing the risk of severe COVID-19. 
Implications of obesity in the COVID-19 pandemic
Obese patients generally respond poorly to vaccinations and anti viral 
treatments.[76] This is most likely due to poor antibody responses 
or poor absorption of vaccines due to increased adiposity.[38] With 
several countries in the process of developing COVID-19 vaccines, 
there is a concern that vaccines may not be effective in obese 
individuals. 
Obese COVID-19 patients also seem to be more contagious than 
lean patients,[77,78] possibly due to the fact that obesity influences the 
viral life cycle and increases virus shedding. Viral load is also likely 
to be greater because of the subdued or delayed immune response, as 
was seen in the H1N1 pandemic.[79,80] Healthcare professionals should 
therefore be cognisant of the consequences of isolation procedures 
and make provision for the likelihood of an increase in an obesogenic 
environment.
The interplay between obesity and COVID-19 has placed an 
additional burden on healthcare systems globally. Obese patients 
have suffered disproportionately from COVID-19, requiring 
hospitalisation and ICU admission and have needed more resources 
such as ventilators.[9,16,18] In low-resource settings such as SA and 
particularly in rural areas, the interplay between COVID-19 
and obesity could place a severe strain on the healthcare system. 
Globally, healthcare systems were overwhelmed by sudden peaks 
in cases, leaving hospitals ill-prepared in terms of resources. These 
observations highlight major challenges faced by healthcare systems 
as a consequence of the ongoing increase in the prevalence of obesity.
Conclusions
Obesity is an independent risk factor for severity and mortality 
in COVID-19. Obesity increases the need for hospitalisation and 
mechanical ventilation. In addition to chronic inflammation, obese 
individuals have defective innate and adaptive immune responses, 
which are the most plausible links between obesity and severe 
COVID-19. Increased expression of ACE2 and DPP4 in adipose 
tissue may increase viral load and drive disease severity. Curbing viral 
transmission via lockdown restrictions, social distancing and reduced 
physical activity may enable behaviour that encourages weight gain. 
The strong association between COVID-19 and obesity-related 
comorbidities highlights a need for healthcare systems to promote 
interventions that address non-communicable diseases, including 
routine health checks, the importance of nutrition and exercise.
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